Pharma results, Crest Nicholson & Compass Group: The Companies and Markets Show
Julian Hofmann opens today’s podcast by unpacking results from AstraZeneca (AZN) and GSK (GSK). AstraZeneca had a particularly strong quarter despite China’s investigation into the importation of cancer drug, Imjudo. GSK’s dividends were up, positive news for income investors, but its vaccine rates have slowed as they…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Investors' Chronicle
See all episodes →
Similar episodes from other shows
More like Investors' Chronicle →
Counting the cost of Marks & Spencer’s cyber-attack, and AstraZeneca versus GSK
Will the vaccine value rally continue for investors?
Covid-19 vaccine makers seek protections, US homebuilder stocks rise, Ant IPO
Big deals in Big Pharma
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.